Bortezomib, a proteasome inhibitor, suppressed cell growth and angiogenesis in SH-SY5Y and CHP126 NB cell lines by modulating the JNK pathway, while its combination with all-trans retinoic acid enhanced tumour growth inhibition in human NB xenografts and a mouse model [63,64,65]. This evidence concerns the gene MAPK8 and neoplasm.